Assignee
AMPHASTAR PHARMACEUTICALS INC
US·25 granted patents·10 pending applications·315 citations·filing 2000–2025
Top patents by PatentIndex Score
35 records- 0193US8367734B1Stable epinephrine suspension formulation with high inhalation delivery efficiencyAMPHASTAR PHARMACEUTICALS INC·Filed 2010·Granted Feb 5, 2013·50 cites·13 claims
- 0290US6793076B1Glass bottle protective enclosureAMPHASTAR PHARMACEUTICALS INC·Filed 2002·Granted Sep 21, 2004·69 cites·22 claims
- 0390US6399087B1Propofol formulation with enhanced microbial inhibitionAMPHASTAR PHARMACEUTICALS INC·Filed 2000·Granted Jun 4, 2002·76 cites·14 claims
- 0486US6418982B1Process of bulk fillingAMPHASTAR PHARMACEUTICALS INC·Filed 2000·Granted Jul 16, 2002·26 cites·10 claims
- 0584US2024225955A1Medication delivery systems and methodsAMPHASTAR PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0683US6827479B1Uniform small particle homogenizer and homogenizing processAMPHASTAR PHARMACEUTICALS INC·Filed 2002·Granted Dec 7, 2004·34 cites·9 claims
- 0776US6457612B1Sealable and manipulable pre-filled disposable pipetteAMPHASTAR PHARMACEUTICALS INC·Filed 2001·Granted Oct 1, 2002·38 cites·22 claims
- 0872US11938089B2Medication delivery systems and methodsAMPHASTAR PHARMACEUTICALS INC·Filed 2020·Granted Mar 26, 2024·0 cites·17 claims
- 0972US7468394B1Sterile pharmaceutical composition and process for a solution of propofol emulsion having microbial growth retardationAMPHASTAR PHARMACEUTICALS INC·Filed 2003·Granted Dec 23, 2008·3 cites·9 claims
- 1071US12370241B2Nasal powder formulation for treatment of hypoglycemiaAMPHASTAR PHARMACEUTICALS INC·Filed 2023·Granted Jul 29, 2025·0 cites·16 claims
- 1166US11446360B2High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the sameAMPHASTAR PHARMACEUTICALS INC·Filed 2019·Granted Sep 20, 2022·0 cites·9 claims
- 1265US7219816B1Easily sealed and opened pre-filled, disposable pipetteAMPHASTAR PHARMACEUTICALS INC·Filed 2003·Granted May 22, 2007·19 cites·7 claims
- 1360US12496272B1Stable epinephrine suspension formulation for inhalation with HFO propellantAMPHASTAR PHARMACEUTICALS INC·Filed 2024·Granted Dec 16, 2025·0 cites·21 claims
- 1459US2024307637A1Intranasal (IN) Delivery Device for Delivering a Medication SolutionAMPHASTAR PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1558US2024299294A1Targeted delivery of effective therapeutic medications to the respiratory tractAMPHASTAR PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1655US12226456B2Nasal powder formulation for treatment of hypoglycemiaAMPHASTAR PHARMACEUTICALS INC·Filed 2019·Granted Feb 18, 2025·0 cites·6 claims
- 1754US12564562B2Injectable epinephrine formulations demonstrating stability over timeAMPHASTAR PHARMACEUTICALS INC·Filed 2022·Granted Mar 3, 2026·0 cites·21 claims
- 1854US10287249B2Methods of resolving racemic mixture to obtain (−)-huperzine AAMPHASTAR PHARMACEUTICALS INC·Filed 2015·Granted May 14, 2019·0 cites·16 claims
- 1951US2023181500A1Naloxone Pharmaceutical Formulations for Intranasal (IN) DeliveryAMPHASTAR PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2051US2024277632A1Epinephrine Pharmaceutical Formulations for Intranasal DeliveryAMPHASTAR PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2150US10322168B2High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the sameAMPHASTAR PHARMACEUTICALS INC·Filed 2016·Granted Jun 18, 2019·0 cites·8 claims
- 2250US2023256099A1Safe Use of Bile Acids and Their Salts as Enhancers for Nasal Delivery of PharmaceuticalsAMPHASTAR PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2349US10406210B2High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the sameAMPHASTAR PHARMACEUTICALS INC·Filed 2016·Granted Sep 10, 2019·0 cites·24 claims
- 2447US11726049B2Small angle x-ray scattering methods for characterizing the iron core of iron carbohydrate colloid drug productsAMPHASTAR PHARMACEUTICALS INC·Filed 2021·Granted Aug 15, 2023·0 cites·24 claims
- 2544US2023271770A1Anti-Viral Pharmaceutical Formulations Administered Via Devices for Lung Targeted DeliveryAMPHASTAR PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2643US11524987B2Highly purified recombinant human insulin (RHI) API and methods of producing the sameAMPHASTAR PHARMACEUTICALS INC·Filed 2019·Granted Dec 13, 2022·0 cites·35 claims
- 2743US9303060B1Methods of preparing intermediate of fluticasone propionateAMPHASTAR PHARMACEUTICALS INC·Filed 2015·Granted Apr 5, 2016·0 cites·24 claims
- 2842US12508229B2Method for preparing stable peptide formulationsAMPHASTAR PHARMACEUTICALS INC·Filed 2020·Granted Dec 30, 2025·0 cites·24 claims
- 2941US12383516B1Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solventAMPHASTAR PHARMACEUTICALS INC·Filed 2025·Granted Aug 12, 2025·0 cites·20 claims
- 3040US2015157649A1Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonateAMPHASTAR PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3140US2015157650A1Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonateAMPHASTAR PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3240US2023119833A1Nmr methods for characterizing iron sucroseAMPHASTAR PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3339US10258573B2Micronized insulin and micronized insulin analogues prepared under acidic conditions, and methods of manufacturing the same under acidic conditionsAMPHASTAR PHARMACEUTICALS INC·Filed 2015·Granted Apr 16, 2019·0 cites·20 claims
- 3436US9447067B2Method of preparing intermediate of salmeterolAMPHASTAR PHARMACEUTICALS INC·Filed 2015·Granted Sep 20, 2016·0 cites·21 claims
- 3532US9873712B2Method of purifying idraparinux sodiumAMPHASTAR PHARMACEUTICALS INC·Filed 2015·Granted Jan 23, 2018·0 cites·25 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →